Theravance Biopharma, Inc. (TBPH)

Theravance Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	105.9	-56.42	-55.19	872.13	-199.43
Depreciation & Amortization	5.64	6.12	6.15	7.71	8.59
Stock-Based Compensation	18.48	21.39	25.37	39.73	62.06
Other Adjustments	-11.94	-2.99	5.01	-1,149	-39.53
Change in Receivables	-27.1	-0.97	-0.69	-2.72	1.8
Changes in Accounts Payable	0.33	0.75	0.01	-1.61	-3.53
Changes in Accrued Expenses	4.01	1.47	-7.1	-15.33	-37.23
Changes in Income Taxes Payable	10.48	9.91	1.1	63.95	-0.19
Changes in Unearned Revenue	-	-	-0.22	-0.19	-11.46
Changes in Other Operating Activities	132.75	9.2	-1.45	-1.75	11.06
Operating Cash Flow	238.54	-11.54	-27	-186.99	-207.86
Capital Expenditures	-0.04	-0.33	-2.49	-0.57	-3.41
Sale of Property, Plant & Equipment	-	-	1.51	1.87	0.01
Proceeds from Sale of Intangible Assets	-	-	-	2.71	-
Purchases of Investments	-248.22	-143.04	-134.53	-103.15	-158.31
Proceeds from Sale of Investments	142.98	155.65	102.81	158.02	286.2
Investing Cash Flow	-105.28	12.28	-32.7	1,154	124.49
Long-Term Debt Issued	-	-	-	24.46	-
Long-Term Debt Repaid	-	-	-	-631.6	-10.73
Net Long-Term Debt Issued (Repaid)	-	-	-	-607.14	-10.73
Issuance of Common Stock	0.79	0.61	0.62	0.8	111.65
Repurchase of Common Stock	-4.03	-3.1	-199.55	-132.28	-9.06
Net Common Stock Issued (Repurchased)	-3.25	-2.5	-198.93	-131.48	102.59
Financing Cash Flow	-3.25	-2.5	-198.93	-758.81	91.86
Net Cash Flow	130.01	-1.75	-258.63	208.21	8.5
Free Cash Flow	238.5	-11.87	-29.49	-187.56	-211.26
FCF Margin	221.93%	-18.43%	-51.35%	-365.29%	-381.96%
Free Cash Flow Per Share	4.63	-0.24	-0.53	-2.55	-3.04
Levered Free Cash Flow	259.06	-29.31	-59.18	138.22	-246.33
Unlevered Free Cash Flow	150.22	-32.26	-66.76	-217.08	-293.81

Updated Mar 19, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q